Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
=== Pubic hair === Pubic hair is often the second noticeable change in puberty, usually within a few months of thelarche. It is referred to as pubarche. The pubic hairs are usually visible first along the labia. The first few hairs are described as Tanner stage 2. Stage 3 is usually reached within another 6–12 months, when the hairs are too numerous to count and appear on the pubic mound as well. By stage 4, the pubic hairs densely fill the "pubic triangle". Stage 5 refers to spread of pubic hair to the thighs and sometimes as abdominal hair upward towards the navel. In about 15% of females, the earliest pubic hair appears before breast development begins.
Dextran hydrogels and dextran conjugate hydrogels are heavily cross-linked polymeric networks that have a strong affinity for water. These gels have soft, elastic physical properties and are biocompatible and biodegradable. Dextran hydrogels have also been shown to be stable and safe in vivo. Glucose-based polymeric gels have the advantage of being able to be chemically or physically modified to improve targeted drug delivery. Swelling is one mechanism by which drugs are released from the dextran hydrogels. Swelling can be reduced by increasing the molecular weight of dextran, leading to a slower drug diffusion rate out of the hydrogel. Swelling can also be lessened by increasing the amount of the conjugated species and introducing ethanol during the cross-linking reaction. Degradation of chemical linkages in the dextran hydrogels is another mechanism by which drugs are released from the polymeric matrices. An increase in degradation of the dextran hydrogel leads to an increase in drug release rate. Degradation of dextran hydrogels specifically is caused by dextranases, which are microbial enzymes mostly located in the colon.
25% of patients treated with arsenic trioxide exhibited symptoms resembling leukocyte activation syndrome, characterized by high fever, shortness of breath, weight gain, pulmonary infiltrates with pleural or pericardial exudation, with or without leukocytosis. High doses of steroids (10 mg dexamethasone intravenously, 2–3 times per day) appear to alleviate these symptoms. 40% of patients treated with arsenic trioxide experienced at least one instance of prolonged QT interval, corrected to over 500 ms. QT interval prolongation can lead to ventricular arrhythmias, such as torsades de pointes. Prior to initiating arsenic trioxide treatment, an ECG should be performed, and blood levels of potassium, calcium, magnesium, and creatinine should be checked. Any abnormalities, particularly a prolonged QT interval on the ECG, should be corrected before starting arsenic trioxide. Any medications that may prolong the QT interval should be discontinued if possible. Patients receiving arsenic trioxide, particularly those at risk for torsades de pointes, should be closely monitored during treatment. If toxicity reaches level 3 (as per National Cancer Institute criteria), treatment should be modified or discontinued before the planned completion of therapy. Patients can resume treatment only after symptoms subside, starting with 50% of the prior daily dose. The dose can be increased to the previous level if no toxicity symptoms appear within 3 days. If toxicity reappears, treatment with arsenic trioxide cannot continue.
Synthesis: The chemical must be produced within the neuron or be present in it as a precursor molecule. Release and response: When the neuron is activated, the chemical must be released and elicit a response in target cells or neurons. Experimental response: Application of the chemical directly to the target cells should produce the same response observed when the chemical is naturally released from neurons. Removal mechanism: There must be a mechanism in place to remove the neurotransmitter from its site of action once its signaling role is complete. However, given advances in pharmacology, genetics, and chemical neuroanatomy, the term "neurotransmitter" can be applied to chemicals that:
Sources: en.wikipedia.org
After the US revoked his existing B1/B2 visa in 2005 and refused to accept his application for an A2 visa, the US State Department affirmed that the visa policy remained unchanged : "(Mr Modi) is welcome to apply for a visa and await a review like any other applicant". Exploring opportunities on how to move the relationship out of a state of morose, Lisa Curtis, senior research fellow for South Asia in the Asian Studies Center of The Heritage Foundation, says that, "the U.S. must first signal its willingness and commitment to collaborating with the new government—and that it will not dwell on the controversy of the 2002 Gujarat riots, which led the U.S. to revoke Modi's visa in 2005." In 2009, the U.S. Commission for International Religious Freedom (USCIRF) report after ignoring the views and decision of independent body (SIT) set up by India's highest judiciary vehemently alleged that there was "significant evidence" linking Narendra Modi to communal riots in the state in 2002 and asked the Obama administration to continue the policy of preventing him from travelling to the United States of America . The Obama administration maintained the 2005 decision taken by the George W. Bush administration to deny Narendra Modi entry into the United States of America. The US Government says that Modi can circumvent the USCIRF sanctions regime by visiting Washington on a Heads of government A1-visa as long as he is the Prime Minister of India.
== Popular uses == Flector (diclofenac epolamine) patch is an NSAID topical patch for the treatment of acute pain due to minor strains, sprains, and contusions. It is also being used in the treatment of pain and inflammation for chronic conditions benefiting from NSAIDs, including fibromyalgia and arthritis. Lidocaine patches, marketed as Lidoderm, relieve the peripheral pain of shingles (herpes zoster). It became commonly used off-label, for pain from acute injuries and chronic pain, although limited by its requirement to be removed for 12 hours, after 12 hours of use. Some experimental studies investigate the use of ceramic dermal patches for local antibiotic delivery to contaminated commercial skin graft patches, and antibiotic dermal patches to deliver local antibiotic to the gum after dental surgery.
Proteins and few polysaccharides have immunogenic properties, which allows them to induce humoral immune responses. Proteins and some lipids/glycolypids can serve as immunogens for cell-mediated immunity. Proteins are significantly more immunogenic than polysaccharides.
Turin is in northwest Italy. It is surrounded on the western and northern front by the Alps and on the eastern front by a high hill that is the natural continuation of the hills of Monferrato. Four major rivers pass through the city: the Po and three of its tributaries, the River Dora Riparia (once known as Duria Minor by the Romans, from the Celtic noun duria, 'water'), the Stura di Lanzo and the Sangone.
=== 23 December === The Netherlands pledged up to 2.5 billion euros to help Ukraine in 2023. This aid was to pay for military equipment and rebuilding critical infrastructure. President Zelenskyy thanked them for this pledge.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.